HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 11, November 2017 – Paediatric Illnesses       » Breakthrough new rice variety announced in Northern China       » Ebola vaccine approved in China       » Study reveals anti-cancer properties of a fungus used in traditional medicine       » Chinese scientists create genetically modified low-fat pigs       » China, Brazil and Russia are riskiest markets for compliance and regulation       » Why are Korean eggs salmonella-free?      
BIOBOARD - SINGAPORE
Understanding abnormal proteins in degenerative diseases
Amyloids, or fibrous aggregates of abnormally folded proteins, are a common feature in degenerative diseases such as Alzheimer's, diabetes and cancer. Amyloids occur naturally in the body, but despite decades of research, their mechanism of formation remains unknown, hampering drug development efforts. Now, a new class of ultrasmall peptides developed by the Institute of Bioengineering and Nanotechnology (IBN) offers scientists a platform for understanding this phenomenon, providing them with the insights required to design more effective treatments for these diseases.

IBN Executive Director Professor Jackie Y. Ying said, “Our researchers have been focusing on creating biomimetic materials for nanomedicine and cell and tissue engineering applications. The novel ultrasmall peptides developed by IBN are not only highly effective as synthetic cell culture substrates, but also as a model for studying the mystery of amyloid formation." Such fundamental understanding could contribute towards advancing medical treatment of amyloid-related disorders.”

First discovered in 2011 by IBN Team Leader and Principal Research Scientist Dr. Charlotte Hauser, the peptides were formed from only 3-7 amino acids, making them the smallest ever reported class of self-assembling aliphatic compounds. Peptides perform a wide range of functions in the body, and are distinguished from proteins based on size. Building on this earlier research, IBN researchers have found a striking similarity between the structure of their synthetic peptides and the protein structure of naturally occurring amyloids in the latest study published in Proceedings of the National Academy of Sciences.

Dr. Hauser elaborated, “This is the first proof-of-concept that our peptides self-assemble in the same way as naturally occurring amyloid sequences. Knowing that the process of amyloid formation is common across various chronic degenerative diseases, our goal is to identify the specific trigger so that we can design the appropriate drugs to inhibit and control the aggregate formation.”

The IBN team collaborated with researchers from the Institute of High Performance Computing and the European Synchrotron Radiation Facility to validate their peptides with the core protein sequences of three diseases: Alzheimer's, diabetes and thyroid cancer.

The results revealed that the mechanism behind the self-assembly of amyloids from smaller intermediate structures into larger amyloid structures was similar to how the IBN peptides were formed. In addition, this study supports the growing evidence that early intermediates are more toxic than the final amyloid fibers, and may even be the driving force behind amyloid formation.

Patent applications have been filed on this research, and the next step of this project is pre-clinical evaluation of ultrasmall peptide therapeutics. IBN will also investigate other amyloid disorders such as corneal dystrophy, which can result in blindness.

Click here for the complete issue.

NEWS CRUNCH  
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
news Novogen becomes Kazia Therapeutics
news Transforming healthcare through innovation: addressing unmet healthcare needs in Asia Pacific
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Paediatric Illnesses
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy